CAS: 89943-82-8; 3-(4-Chlorophenyl)-6-Methyl-1,3-Dihydrofuro[3,4-C]Pyridin-7-Ol

该化合物是属于二尿素类的合成抗血压剂,特别是类似于呋喃的磺酰胺衍生物,它具有血管和营养特性,通过减少外围血管抗药性和促进钠排泄,有效地管理高血压.该化合物显示出一种有利的药效动因特征,可快速吸收和中度半衰期,确保持续的治疗效果.其行动机制包括抑制纳+-K+-2Cl-Symporter在Henle环形的上肢,从而减少了液体的留存.

结构式图片

欧盟法规

ECHA物质C&L通报

上下游产品

(+/-)-4-氯苯基-5-[(3,4-异丙基亚基)-2-甲基吡啶]甲醇 (+)-2,2,8-Trimethyl-5-(4-Chloro-α-Hydroxybenzyl)-Pyrido-[4,3-E]-1,3-Dioxane 133545-64-9

合成工艺路线路线简述

    📜Methyl (2S,3R,4S,5R,6R)-3,4,5-Triacetyloxy-6-[[3-(4-Chlorophenyl)-6-Methyl-1,3-Dihydrofuro[3,4-C]Pyridin-7-Yl]Oxy]Oxane-2-Carboxylate 反应生成 西氯他宁
    参考文献:Esanu,Andre;Eck,Charles
    标题:Esanu,Andre;Eck,Charles

    海关参考信息

    专利信息


    专利号:US-2008287407-A1
    优先权日:2003-12-10
    标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
    发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
    权利人:NITROMED INC
    摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

    专利号:US-5043448-A
    优先权日:1989-07-27
    标 题:Asymmetric synthesis of furo(3,4-c) pyridine derivatives
    发明人:ECK CHARLES
    权利人:SCRAS
    摘要:The invention relates to a method for the preparation of a non-racemic furo [3,4-c] pyridine derivatives of the formula I ##STR1## wherein R 1 , R 2 and R 3 stand for various substitutents, comprising adding a concentrated strong acid to a solution of a non-racemic compound of the formula II ##STR2## in an amount sufficient to catalyze a deprotection/cyclodehydration. These compounds are known antihypertensives.

    专利号:AT-399151-B
    优先权日:1989-07-27
    标题:ASYMMETRICAL SYNTHESIS OF FURO (3,4-C) PYRIDINE DERIVATIVES

    专利号:CN-101678118-A
    优先权日:2006-10-05
    标 题:Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

    专利号:NL-9001612-A
    优先权日:1989-07-27
    标 题:ASYMMETRICAL SYNTHESIS OF FURO3,4-C PYRIDINE DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THE NON-RACEMIC, PHARMACEUTICALLY ACTIVE DERIVATIVES.

    专利号:SE-509680-C2
    优先权日:1989-07-27
    标 题:Asymmetric synthesis of furo (3,4-c) pyridine derivatives

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Choi EY, Ro Y, Choi JW, Kang CM, Kim GH. Cicletanine-induced hyponatremia and hypokalemia in kidney transplant patients. Kidney Res Clin Pract. 2016 Sep;35(3):142-6. doi: 10.1016/j.krcp.2016.05.004. Epub 2016 May 25.
    2: Kalinowski L, Szczepańska-Konkel M, Jankowski M, Angielski S. Cicletanine: new insights into its pharmacological actions. Gen Pharmacol. 1999 Jul;33(1):7-16. doi: 10.1016/s0306-3623(98)00257-2. 19(2):181-9. doi: 10.1097/00005344-199202000-00005. 13(5):571-6. doi: 10.1111/j.1472-8206.1999.tb00363.x. 26(3):236-41. doi: 10.1046/j.1440-1681.1999.03021.x. 43(25):2103-15. doi: 10.1016/0024-3205(88)90360-8. 305(2):G163-71. doi: 10.1152/ajpgi.00003.2013. Epub 2013 May 2.
    8: Wagner F, Malice MP, Wiegert E, McGrath HE, Gildea J, Mitta S, Van Dyck K, De Lepeleire I, Johnson-Levonas AO, Sisk CM, Fernandez R, Greenwalt DM, Beals C, Carey RM, Nunes I. A comparison of the natriuretic and kaliuretic effects of cicletanine and hydrochlorothiazide in prehypertensive and hypertensive humans. J Hypertens. 2012 Apr;30(4):819-27. doi: 10.1097/HJH.0b013e32835022a8. 21 Suppl

    合成参考文献


    参考文献:10.2165/00003495-199300462-00013
    摘要:Safar ME, Lévy BI. Mechanical function and histological structure of the arterial wall. The response to antihypertensive treatment. Drugs. 1993;46 Suppl 2():68–74. doi: 10.2165/00003495-199300462-00013.
    参考文献:10.1023/a:1007835821228
    摘要:Reyes AJ, Taylor SH. Diuretics in cardiovascular therapy: the new clinicopharmacological bases that matter. Cardiovasc Drugs Ther. 1999 Sep;13(5):371–98. doi: 10.1023/a:1007835821228.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知